ChemoHyperthermia for Non Muscle Invasive Bladder Cancer & unique HIPEC+Agitation. UK company bringing innovative cancer treatments to patients in 40+ countries
A Mayo Clinic study has found significant declines in body fat up to 3 years before pancreatic cancer diagnosis, suggesting body composition analysis could help identify at-risk patients.
👉 https://t.co/L16ymofBbE
#PancreaticCancerAwarenessMonth#HIPEC#CombatCancer
Could better colonoscopy practices improve bowel cancer detection in IBD? A major UK study has found greater endoscopist experience, longer examination times and dye-based chromoendoscopy were linked to improved polyp detection.
👉 https://t.co/iFLPxzRSpe
#HIPEC#CombatCancer
Bladder cancer is now the 8th most frequently diagnosed cancer globally – up from 9th on 2022 estimates, and 10th on 2020 data.
👉 The full GLOBOCAN 2024 report is at: https://t.co/yRVaf1lDgG
#medicalinnovation#bladdercancer#HIVEC#CombatCancer
We're at the @BAUNnurses Annual Conference in Manchester from 18-20 October. Visit us at Booth #36 to find out more about our Combat BRS #HIVEC® hyperthermic chemo delivery system with mitomycin C for NMIBC, plus the latest news on our phase 3 @HIVEC_HEAT trial.
#CombatCancer
Inspired by cancer-detecting sniffer dogs, electronic nose technology could be used to diagnose bladder cancer. A study of 335 participants achieved 87.5% accuracy, 81.8% sensitivity and 95.1% specificity using urine samples.
👉https://t.co/FzrGmIyoWS
#HIVEC#CombatCancer
Researchers at @MIT and @JohnsHopkins have developed a handheld microfluidic device that collects living cells from specific areas of the fallopian tube, potentially enabling earlier diagnosis.
👉https://t.co/MRVUSM93md
#HIPEC#CombatCancer
💥 @HIVEC_HEAT trial update – 3 new sites have opened! The phase 3 trial is evaluating the efficacy and safety of the Combat BRS (bladder recirculating system) HIVEC® treatment with mitomycin C for NMIBC as a bladder-sparing alternative in BCG-unresponsive patients.
#CombatCancer
Meet us at Booth E19 at the German Urological Congress in Düsseldorf today and tomorrow to find out more about our Combat BRS HIVEC® treatment for BCG-unresponsive NMIBC – including updates on our phase 3 @HIVEC_HEAT trial.
@DGUrologie#bladdercancer#HIVEC#CombatCancer
It's #UrologyAwarenessMonth, raising the profile of urological diseases, including bladder cancer. Caught early, bladder cancer survival rates can be as high as 90%. Blood in the urine (haematuria) is the main symptom and should always be checked by a GP.
#HIVEC#CombatCancer
Great news @gloshospitals – a third participant recruited to the @HIVEC_HEAT phase 3 trial assessing Combat’s HIVEC® treatment of BCG-unresponsive non-muscle-invasive bladder cancer!
#HIVEC#CombatCancer
The Combat PRS+ (Peritoneal Recirculation System +Agitation) optimises HIPEC – hyperthermic intraperitoneal chemotherapy – to improve drug penetration into peritoneal tumours, including colorectal, ovarian and pancreatic cancer.
#HIPEC#CombatCancer
The Combat BRS is our HIVEC® drug-delivery treatment with mitomycin C for NMIBC, currently being evaluated in the @HIVEC_HEAT phase 3 trial. It uses clinical hyperthermia to substantially increase chemotherapy effectiveness vs room-temperature instillation.
#HIVEC#CombatCancer
Delighted to report the recruitment of our 11th patient into the phase 3 @HIVEC_HEAT trial for Combat’s HIVEC® treatment of BCG-unresponsive non-muscle-invasive bladder cancer!
#HIVEC#CombatCancer
As use of GLP-1s becomes increasingly widespread, what do we really know about their relationship with #PancreaticCancer? A new review finds that current clinical evidence is reassuring, but longer-term studies remain essential.
👉https://t.co/VqSdAEG6bl
#HIPEC#CombatCancer
Delighted that @imperial_n86543 has recruited its first @HIVEC_HEAT patient for our phase 3 trial investigating the efficacy & safety of the Combat BRS #HIVEC® treatment with mitomycin C for NMIBC as a bladder-sparing alternative in BCG-unresponsive patients.
#CombatCancer
Supported with a @bowelcanceruk grant, researchers at @ICR_London and St Mark’s Hospital London are developing a non-invasive way to predict bowel cancer risk in people with IBD, who have a higher risk of developing bowel cancer.
👉https://t.co/fFXl3Sx8fj
#HIPEC#CombatCancer
Delighted to announce the recruitment of another participant to the @HIVEC_HEAT phase 3 trial for patients with BCG-unresponsive NMIBC.
#HIVEC#HIVECHEAT#CombatCancer